** Shares of medical test maker  LMNX.O  rise 4.8% to $27.70
premarket
    ** LMNX receives $642,450 from the Biomedical Advanced
Research and Development Authority (BARDA) to fund development,
testing and submission for an Emergency Use Authorization (EUA)
for its COVID-19 detection test  urn:newsml:reuters.com:*:nPn1DrHzPa
    ** The test, ARIES SARS-CoV-2 Assay, is designed to generate
results in approximately two hours
    **  Luminex intends to price the test below current
government reimbursement levels
    ** BARDA is part of U.S. Department of Health and Human
Services and is tasked with protecting the country against
emerging infectious diseases and other threats
    ** Last week, Luminex received a BARDA contract and an FDA
EUA for another coronavirus test that provides results for up to
96 samples in approximately four hours
    ** Up to Monday's close, LMNX rose ~14% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))